Tango Therapeutics, Inc. (TNGX) Research

Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.

Market snapshot

Symbol
TNGX
Price
$27.97
Day change
-13.38%
Market cap
$3.5B
P/E ratio
-37.45x
52-week range
4.6-34.39
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$42.70

Recent news

  • Tango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer Treatment

    Tango Therapeutics stock soars after the biotech company announces initial data from its ongoing study on pancreatic cancer. An analyst calls the results ‘unprecedented.

  • Tango Therapeutics, American Battery Technology, Intel And Other Big Stocks Moving Higher On Monday

    U.S. stocks were higher, with the Nasdaq Composite gaining around 1% on Monday.

  • Tango Therapeutics' pancreatic cancer drug combo shows promise in study

    Tango Therapeutics said on Monday an experimental drug combination showed strong early results in a small study of patients with advanced pancreatic ​cancer and that it plans to advance the treatment into ‌late-stage testing.

Peer companies

  • Bicara Therapeutics Inc. Common Stock (BCAX)
  • EyePoint Pharmaceuticals, Inc. (EYPT)
  • Fortrea Holdings Inc. (FTRE)
  • Kodiak Sciences Inc. (KOD)
  • Kura Oncology, Inc. (KURA)
  • Nurix Therapeutics, Inc. (NRIX)
  • ProKidney Corp. (PROK)
  • Septerna, Inc. (SEPN)

Recent insider activity

  • Ketchum John B — A-Award (25000 shares) on 2026-06-05
  • Ketchum John B — A-Award (4000 shares) on 2026-06-05
  • Calhoun Lesley Ann — A-Award (25000 shares) on 2026-06-05
  • Calhoun Lesley Ann — A-Award (4000 shares) on 2026-06-05
  • Rothenberg Mace — A-Award (4000 shares) on 2026-06-05

Open Tango Therapeutics, Inc. (TNGX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.